文献速递呼吸道感染

欧洲支气管扩张症登记研究中吸入糖皮质激素的使用情况

Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).
PubMed 文献 · Thorax · 2025-05-20

52.3%患者基线处方ICS,排除哮喘、慢阻肺和ABPA后仍有32.7%使用ICS,各国使用率17%至85%不等。ICS使用者整体未降低急性加重或住院风险,但血嗜酸性粒细胞升高亚组急性加重频率显著降低(相对风险0.70,95%CI 0.59至0.84,p<0.001)。

要点

  • 支气管扩张症患者ICS使用普遍,超出现行指南推荐范围。
  • 整体ICS未降低急性加重或住院风险。
  • 血嗜酸性粒细胞升高者ICS可能减少急性加重频率。

核心结论

  • ICS在支气管扩张症中广泛使用,包括指南未推荐的患者。
  • ICS整体未降低急性加重或住院风险,但血嗜酸性粒细胞升高者可能获益。

研究设计与样本

  • 基线分组为ICS使用者和非使用者,随访最长5年,评估急性加重、住院和死亡。

主要发现

  • 排除哮喘、慢阻肺和ABPA后,3174/9715例(32.7%)仍使用ICS。
  • 各国ICS使用率范围为17%至85%。
  • ICS使用者疾病更严重,肺功能更差、BSI评分更高、基线急性加重更频繁(p<0.0001)。
  • 血嗜酸性粒细胞升高亚组ICS使用者急性加重频率降低(相对风险0.70,95%CI 0.59至0.84,p<0.001)。

临床怎么用

  • 处方ICS应评估是否符合指南推荐(合并哮喘、ABPA或慢阻肺)。
  • 对无指南推荐者,可考虑血嗜酸性粒细胞水平指导ICS决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Current bronchiectasis guidelines advise against the use of inhaled corticosteroids (ICS) except in patients with associated asthma, allergic bronchopulmonary aspergillosis (ABPA) and/or chronic obstructive pulmonary disease (COPD). This study aimed to describe the use of ICS in patients with bronchiectasis across Europe. METHODS: Patients with bronchiectasis were enrolled into the European Bronchiectasis Registry from 2015 to 2022. Patients were grouped into ICS users and non-users at baseline and clinical characteristics associated with ICS use were investigated. Patients were followed up for clinical outcomes of exacerbation, hospitalisation and mortality for up to 5 years. We evaluated if elevated blood eosinophil counts (above the laboratory upper limit of normal) modified the effect of ICS on exacerbations. RESULTS: 19 324 patients were included for analysis and 10 109 (52.3%) were recorded as being prescribed ICS at baseline. After exclusion of patients with a history of asthma, COPD and/or ABPA, 3174/9715 (32.7%) patients with bronchiectasis were prescribed ICS. Frequency of ICS use varied across countries, ranging from 17% to 85% of included patients. ICS users had more severe disease, with significantly worse lung function, higher Bronchiectasis Severity Index scores and more frequent exacerbations at baseline (p<0.0001). Overall, ICS users did not have a reduced risk of exacerbation or hospitalisation during follow-up, but a significant reduction in exacerbation frequency was observed in the subgroup of ICS users with elevated blood eosinophil counts (relative risk 0.70, 95% CI 0.59 to 0.84, p<0.001). CONCLUSION: ICS use is common in bronchiectasis, including in those not currently recommended ICS according to bronchiectasis guidelines. ICS use may be associated with reduced exacerbation frequency in patients with elevated blood eosinophils.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Pollock, Polverino, Dhar, et al. Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC). Thorax. 2025. PMID: 40122611. doi:10.1136/thorax-2024-221825

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。